{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:06:58Z","timestamp":1790006818905,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04151-y","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:46:12Z","timestamp":1786477572000},"page":"2623-2640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches"],"prefix":"10.1007","volume":"43","author":[{"given":"Petra","family":"Booij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarja","family":"Nurmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Creasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeshna","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Zdravkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Verdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Soba\u0144tka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6124-2432","authenticated-orcid":false,"given":"Mary Kate","family":"Bielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"4151_CR1","unstructured":"Product Quality Research Institute (PQRI). Safety thresholds and best practices for extractables and leachables in orally inhaled and nasal drug products. 2006. Available from: https:\/\/pqri.org\/wp-ontent\/uploads\/2015\/08\/pdf\/LE_Recommendations_to_FDA_09-29-06.pdf. Accessed 23 Dec 2025."},{"key":"4151_CR2","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH M7(R2) Guideline for assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. 2023. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf. Accessed 23 Dec 2025."},{"key":"4151_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2021.116286","volume":"141","author":"G Singh","year":"2021","unstructured":"Singh G, Lu D, Liu C, Hower D. Analytical challenges and recent advances in the identification and quantitation of extractables and leachables in pharmaceutical and medical products. TrAC Trends Anal Chem. 2021;141:116286. https:\/\/doi.org\/10.1016\/j.trac.2021.116286.","journal-title":"TrAC Trends Anal Chem"},{"key":"4151_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mas.21910","author":"C Mase","year":"2024","unstructured":"Mase C, Sueur M, Lavanant H, R\u00fcger CP, Giusti P, Afonso C. Ion source complementarity for characterization of complex organic mixtures using Fourier transform mass spectrometry: a review. Mass Spectrom Rev. 2024. https:\/\/doi.org\/10.1002\/mas.21910.","journal-title":"Mass Spectrom Rev"},{"key":"4151_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202300571","author":"ML Williams","year":"2023","unstructured":"Williams ML, Olomukoro AA, Emmons RV, Godage NH, Gionfriddo E. Matrix effects demystified: strategies for resolving challenges in analytical separations of complex samples. J Sep Sci. 2023. https:\/\/doi.org\/10.1002\/jssc.202300571.","journal-title":"J Sep Sci"},{"key":"4151_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.06.063","volume":"205","author":"C Reymond","year":"2019","unstructured":"Reymond C, Le Masle A, Colas C, Charon N. A rational strategy based on experimental designs to optimize parameters of a liquid chromatography-mass spectrometry analysis of complex matrices. Talanta. 2019;205:120063. https:\/\/doi.org\/10.1016\/j.talanta.2019.06.063.","journal-title":"Talanta"},{"key":"4151_CR7","unstructured":"Product Quality Research Institute (PQRI). Safety thresholds and best demonstrated practices for extractables and leachables in parenteral drug products (intravenous, subcutaneous, and Intramuscular). 2021. Available from: https:\/\/pqri.org\/wp-content\/uploads\/2022\/03\/PQRI-PDP-Recommendation-2022.pdf. Accessed 23 Dec 2025."},{"issue":"5","key":"4151_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5731\/pdajpst.2021.012693","volume":"76","author":"MJ Masuda-Herrera","year":"2022","unstructured":"Masuda-Herrera MJ, Bercu JP, Broschard TH, Burild A, Hasselgren C, Parris P, et al. Development of duration-based non-mutagenic thresholds of toxicological concern (TTCs) relevant to parenteral extractables and leachables (E&Ls). PDA J Pharm Sci Technol. 2022;76(5):369\u201383. https:\/\/doi.org\/10.5731\/pdajpst.2021.012693.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4151_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105776","author":"P Parris","year":"2025","unstructured":"Parris P, et al. Comprehensive extractables and leachables sensitization analysis and practical application of a risk-based approach to sensitization assessment for parenteral drug products. Regul Toxicol Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.yrtph.2025.105776.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"4151_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.5731\/pdajpst.2022.012811","volume":"78","author":"P Parris","year":"2024","unstructured":"Parris P, et al. Sensitization assessment of extractables and leachables in pharmaceuticals: ELSIE database analysis. PDA J Pharm Sci Technol. 2024;78(4):399\u2013444. https:\/\/doi.org\/10.5731\/pdajpst.2022.012811.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4151_CR11","unstructured":"Paskiet D. Introduction to PODP recommendations: risk based concepts. In: PQRI PODP Extractables & Leachables Workshop; 2018 Apr; Rockville (MD). Presentation. Available from https:\/\/pqri.org\/wp-content\/uploads\/2018\/04\/2-PQRI-Paskiet-Final.pdf. Accessed 31 Mar 2026."},{"key":"4151_CR12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q3E draft guideline for assessment and control of extractables and leachables for pharmaceuticals and biologics, Step 2. 2025. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q3E_EWG_Step2_DraftGuideline_2025_0704.pdf. Accessed 23 Dec 2025."},{"key":"4151_CR13","unstructured":"United States Pharmacopeia (USP). General Chapter <1664> Assessment of drug product leachables associated with pharmaceutical packaging\/delivery systems. Rockville (MD): U.S. Pharmacopeial Convention; 2020. Available from: https:\/\/doi.usp.org\/USPNF\/USPNF_M7127_03_01.html. Accessed 23 Dec 2025."},{"issue":"5","key":"4151_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103764","volume":"114","author":"SA Zdravkovic","year":"2025","unstructured":"Zdravkovic SA, Kikandi S, Fu Q, Jana B, Creasy J, Flick A, et al. Procedural modifications proposed for the screening of substances extracted from pharmaceutical packaging systems and medical devices with the goal of improving inter-laboratory consistency of the data generated. J Pharm Sci. 2025;114(5):103764. https:\/\/doi.org\/10.1016\/j.xphs.2025.103764.","journal-title":"J Pharm Sci"},{"key":"4151_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-025-05946-5","author":"MG Rozio","year":"2025","unstructured":"Rozio MG, Angelini D, Carrara S. Uncertainty factors and relative response factors: correcting detection and quantitation bias in extractables and leachables studies. Anal Bioanal Chem. 2025. https:\/\/doi.org\/10.1007\/s00216-025-05946-5.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"4151_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5731\/pdajpst.2021.012692","volume":"76","author":"D Jenke","year":"2022","unstructured":"Jenke D, Christiaens P, Beusen JM, Verlinde P, Baeten J. A practical derivation of the uncertainty factor applied to adjust the extractables\/leachables analytical evaluation threshold (AET) for response factor variation. PDA J Pharm Sci Technol. 2022;76(3):178\u201399. https:\/\/doi.org\/10.5731\/pdajpst.2021.012692.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4151_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114676","volume":"213","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hu Y, Yuill EM, Marriott AS, Chadwick J, et al. Circumventing glass vial and diluent effects on solution stability of small molecule analytes during analytical method development and validation. J Pharm Biomed Anal. 2022;213:114676. https:\/\/doi.org\/10.1016\/j.jpba.2022.114676.","journal-title":"J Pharm Biomed Anal"},{"key":"4151_CR18","unstructured":"Oktem B, Nahan K, Sussman EM, Yun BH, Patabandige MW, Wickramasekara S. Considerations for uncertainty factor determination in medical device extractables analysis. In: FDA Science Forum: Science as the Foundation for Protecting and Promoting Public Health. 2021. https:\/\/www.fda.gov\/science-research\/fdascience-forum\/considerations-uncertainty-factor-determination-medical-device-extractables-analysis. Accessed 23 Jul 2026."},{"issue":"3","key":"4151_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5731\/pdajpst.2020.012047","volume":"75","author":"M Jordi","year":"2021","unstructured":"Jordi M, Heise T. An analytical strategy based on multiple complementary and orthogonal chromatographic and detection methods (multidetector approach) to effectively manage the analytical evaluation threshold (AET). PDA J Pharm Sci Technol. 2021;75(3):289\u2013301. https:\/\/doi.org\/10.5731\/pdajpst.2020.012047.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4151_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4236\/ajac.2024.1512025","volume":"15","author":"K Hotha","year":"2024","unstructured":"Hotha K, Ramamoorthy S. Strengthening extractable and leachable study submissions: best practices to avoid regulatory deficiencies. Am J Anal Chem. 2024;15:368. https:\/\/doi.org\/10.4236\/ajac.2024.1512025.","journal-title":"Am J Anal Chem"},{"issue":"3","key":"4151_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.xphs.2023.12.024","volume":"113","author":"A Arroyo","year":"2024","unstructured":"Arroyo A, Booij P, Woldemariam G, Bruen U, Creasey J, Stanard B, et al. Cell and gene therapies: challenges in designing extractables and leachables studies and conducting safety assessments. J Pharm Sci. 2024;113(3):513\u201322. https:\/\/doi.org\/10.1016\/j.xphs.2023.12.024.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4151_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.5731\/pdajpst.2016.007195","volume":"71","author":"DR Jenke","year":"2017","unstructured":"Jenke DR, Rabinow BE. Proper accounting for surface area to solution volume ratios in exaggerated extractions. PDA J Pharm Sci Technol. 2017;71(3):225\u201333. https:\/\/doi.org\/10.5731\/pdajpst.2016.007195.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4151_CR23","volume-title":"ISO 10993-18:2020, Biological evaluation of medical devices \u2014 Part 18: chemical characterization of medical device materials within a risk management process","author":"International Organization for Standardization (ISO)","year":"2020","unstructured":"International Organization for Standardization (ISO). ISO 10993-18:2020, Biological evaluation of medical devices \u2014 Part 18: chemical characterization of medical device materials within a risk management process. Geneva (Switzerland): ISO; 2020."},{"key":"4151_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s41783-023-00157-8","volume":"7","author":"N Sharma","year":"2023","unstructured":"Sharma N, Brahmankar Y, Babar D, Bhogle T, Mirase R, Rathod R, et al. Systematic approaches on extractable and leachable study designs in pharmaceuticals and medical devices: a review. J Package Technol Res. 2023;7:127\u201345. https:\/\/doi.org\/10.1007\/s41783-023-00157-8.","journal-title":"J Package Technol Res"},{"key":"4151_CR25","unstructured":"United States Pharmacopeia (USP). General Chapter <1663> Assessment of extractables associated with pharmaceutical packaging\/delivery systems. Rockville (MD): U.S. Pharmacopeial Convention; 2020. Available from: https:\/\/doi.usp.org\/USPNF\/USPNF_M7126_03_01.html. Accessed 23 Dec 2025."},{"key":"4151_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2021.116995","volume":"345","author":"J Li","year":"2022","unstructured":"Li J. Evaluation of blood simulating solvents in extractables and leachables testing for chemical characterization of medical devices based on Abraham general solvation model. J Mol Liq. 2022;345:116995. https:\/\/doi.org\/10.1016\/j.molliq.2021.116995.","journal-title":"J Mol Liq"},{"key":"4151_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107108","volume":"210","author":"N Heider","year":"2025","unstructured":"Heider N, Soba\u0144tka A. PredicDiff\u2122: a computational tool for the prediction of PERLs concentrations based on extractables data. Eur J Pharm Sci. 2025;210:107108. https:\/\/doi.org\/10.1016\/j.ejps.2025.107108.","journal-title":"Eur J Pharm Sci"},{"key":"4151_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/9783527621422","author":"OG Piringer","year":"2008","unstructured":"Piringer OG, Baner AL. Plastic packaging: interactions with food and pharmaceuticals. 2008. https:\/\/doi.org\/10.1002\/9783527621422.","journal-title":"Plastic packaging: interactions with food and pharmaceuticals"},{"key":"4151_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2024.100158","volume":"6","author":"J Li","year":"2024","unstructured":"Li J. Application of Abraham\u2019s solvation parameter model to extractables and leachables studies in pharmaceutical and medical device industries: a tutorial. J Chromatogr Open. 2024;6:100158. https:\/\/doi.org\/10.1016\/j.jcoa.2024.100158.","journal-title":"J Chromatogr Open"},{"key":"4151_CR30","unstructured":"U.S. Food and Drug Administration (FDA). Guidance for Industry: Expedited programs for serious conditions \u2013 drugs and biologics. Silver Spring (MD): Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER); 2014. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf. Accessed 23 Dec 2025."},{"key":"4151_CR31","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH S9 Guideline for nonclinical evaluation for anticancer pharmaceuticals - questions and answers. 2010. Available from: https:\/\/database.ich.org\/sites\/default\/files\/S9_Q%26As_Step4_Presentation.pdf. Accessed 23 Dec 2025."},{"key":"4151_CR32","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q3D(R2) Guideline for elemental impurities. 2022. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q3D-R2_Guideline_Step4_2022_0308.pdf.\u00a0Accessed 23 Dec 2025."},{"key":"4151_CR33","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q2 validation of analytical procedures. 2023. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130_ErrorCorrection_2025.pdf. Accessed 01 Jan 2026."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04151-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:47:16Z","timestamp":1790005636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04151-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04151-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests for this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}